OPPM
KALV

Opus Point Partners Management’s KalVista Pharmaceuticals KALV Stock Holding History

Opus Point Partners Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,250
Closed -$63K – 56
2015
Q4 		$63K Buy
+1,250
New +$65.4K 0.04% 56

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opus Point Partners Management's KALV Position: Q1 2016 in Review

Opus Point Partners Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2016, closing a stake of 1,250 shares — an estimated $63K sold.

Opus Point Partners Management first reported a position in KALV in Q4 2015 and held it in 1 quarter. The position peaked at $63K in Q4 2015. 32 funds tracked by Wall St. Rank hold KALV as of Q1 2016.

  • Opus Point Partners Management reported no remaining KalVista Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Opus Point Partners Management sold 1,250 KalVista Pharmaceuticals shares in Q1 2016, an estimated $63K.
  • Opus Point Partners Management first reported a position in KalVista Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Opus Point Partners Management's KalVista Pharmaceuticals position peaked at $63K in Q4 2015.
  • 32 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2016.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.